Brainstorm Cell Therapeutics Inc.
BCLI
$1.00
$0.011.01%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.47% | -27.85% | -17.95% | -32.60% | -28.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.38% | -27.61% | -14.88% | -18.11% | -26.98% |
| Operating Income | 16.38% | 27.61% | 14.88% | 18.11% | 26.98% |
| Income Before Tax | 8.09% | 13.67% | 11.32% | 23.77% | 10.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.09% | 13.67% | 11.32% | 23.77% | 10.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.09% | 13.67% | 11.32% | 23.77% | 10.18% |
| EBIT | 16.38% | 27.61% | 14.88% | 18.11% | 26.98% |
| EBITDA | 16.37% | 27.76% | 14.83% | 18.09% | 27.14% |
| EPS Basic | 47.58% | 53.36% | 49.03% | 56.59% | 45.89% |
| Normalized Basic EPS | 47.58% | 53.35% | 49.03% | 56.59% | 45.89% |
| EPS Diluted | 47.58% | 53.36% | 49.03% | 56.59% | 45.89% |
| Normalized Diluted EPS | 47.58% | 53.35% | 49.03% | 56.59% | 45.89% |
| Average Basic Shares Outstanding | 69.87% | 88.70% | 84.37% | 77.88% | 68.16% |
| Average Diluted Shares Outstanding | 69.87% | 88.70% | 84.37% | 77.88% | 68.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |